多药耐药相关蛋白在胃癌中的表达及其临床意义

• 作 者: 刘忠民 毕维民 王明玉 陈廷武 寿楠海 姜希宏 徐克森
• 机 构: 泰安市中心医院!271000,泰安市中心医院!271000,泰安市中心医院!271000,泰安市中心医院!271000,山东医科大学附属医院,山东医科大学附属医院,山东医科大学附属医院
• 出 处: 山东医药
• 发表日期: 2000年03期
• 关键词: 胃肿瘤 多药耐药相关蛋白 免疫组织化学 流式细胞术

采用免疫组化法检测36例胃癌患者癌组织中的多药耐药相关蛋白(MRP)表达情况,其中14例同时应用流式细胞术(FCM)检测MRP表达率。结果36例胃癌组织中29例MRP表达阳性,阳性率为80.6%,MRP表达与肿瘤大小、组织学类型、淋巴结转移、浸润深度及TNM分期无关。FCM检测结果显示,MRP的平均表达率为39.1±13.4%,明显高于正常对照(11.9±2.5%,P<0.01)和阴性对照(1.9±0.1%,P<0.01)。认为胃癌组织存在较高的原发耐药,MRP测定有助于选择化疗药物。

Immunohistochemistry was used to detect the expression of multidrug resistance-associated protein (MRP) in cancer tissues of 36 patients with gastric cancer, and 14 cases were simultaneously examined by flow cytometry (FCM) for the expression of MRP. Results The expression of MRP was positive in 29 cases of gastric cancer. The positive rate was 80.6%. The expression of MRP was not associated with tumor size, histological type, lymph node metastasis, invasion depth and TNM stage. The results of FCM showed that the average expression rate of MRP was 39.1±13.4%, which was significantly higher than the normal control (11.9±2.5%, P<0.01) and the negative control (1.9±0.1%, P<0.01). It is considered that there is a high level of primary drug resistance in gastric cancer, and MRP assay is helpful for the selection of chemotherapy drugs.